From innovation to commercialization. Dyadic President & COO Joe Hazelton discusses our commercial strategy, growing protein markets, and progress with partners worldwide. $DYAI #Biotechnology #ProteinProduction

Dyadic $DYAI Q2 2026: Commercialization momentum continues. We’re expanding recombinant protein shipments, initial sales and partner commercialization while improving manufacturing productivity and advancing strategic collaborations. Our focus: converting platform capabilities into commercial opportunities and potential recurring revenue. Q2 Results: dyadic.com/dyadic-announces-… #DYAI #Biomanufacturing #Biotechnology

Dyadic is expanding its commercial Food & Nutrition pipeline with a new strategic development and commercial license agreement for an additional precision-fermented dairy protein. Building on recombinant bovine chymosin and alpha-lactalbumin programs, Dapibus™ continues to demonstrate its potential as a repeatable precision fermentation platform for food proteins. dyadic.com/dyadic-expands-co… $DYAI #PrecisionFermentation #FoodTech #Biotechnology

Dyadic announced a key milestone for its proprietary C1™ platform: stable cell pools and purified Bundibugyo Ebola antigens produced in ~15 days from plasmids for preclinical evaluation by Scripps Research—demonstrating the potential for faster biologics development and manufacturing. $DYAI 🔗 dyadic.com/dyadic-develops-s… #Biotechnology #Biologics #Vaccines #ProteinProduction #Ebola #GlobalHealth #Manufacturing #Innovation

We're expanding our #Bioindustrial pipeline. Today, Dyadic announced a new proprietary industrial enzyme program for advanced cellulose processing, building on the launch of EN3ZYME™and showcasing the scalability of our Dapibus™ platform. The program targets applications including: 🌱 Pulp biorefining 🧪 Microcrystalline cellulose 🔬 Nanocellulose Our strategy continues to focus on building a diversified portfolio through proprietary products, partnerships, contract manufacturing, and technology licensing. Read more: dyadic.com/dyadic-expands-bi… $DYAI #IndustrialEnzymes #Biotechnology #PrecisionFermentation #Biomanufacturing #Sustainability #Cellulose #BioFlorida

Global collaborations continue to validate the potential of Dyadic's proprietary C1 platform to accelerate biologics manufacturing. Our latest update highlights progress with the Gates Foundation, CEPI, Scripps Research and the European Vaccines Hub as we continue advancing faster, scalable and potentially lower-cost recombinant protein production. Read more: dyadic.com/global-collaborat… $DYAI #Biotech #Biologics #ProteinEngineering #Innovation #LifeSciences #BioFlorida

We're pleased to announce an important milestone as Dyadic strengthens its intellectual property portfolio in Japan while advancing business development activities in one of the world's leading biotechnology markets. As we continue executing our strategy to become a global provider of recombinant protein solutions, we're expanding relationships with prospective partners across life sciences, food & nutrition, industrial biotechnology and biopharma. Read the full announcement:dyadic.com/dyadic-expands-ip… $DYAI #Biotech #LifeSciences #Biopharma #ProteinEngineering #Japan #Innovation #BioFlorida

Dyadic and Scripps Research are collaborating on rapid-response hantavirus antibody and vaccine development using Dyadic’s proprietary C1 platform for fast, scalable biologic production. Collaboration builds on prior Andes virus work and funded pandemic preparedness programs involving Gates Foundation, CEPI & ZAPI. Read the full announcement here:dyadic.com/dyadic-and-scripp… $DYAI

Dyadic Applied BioSolutions will be participating in the upcoming Sidoti Virtual Investor Conference on May 20-21. President & COO Joe Hazelton will present company updates and meet virtually with investors throughout the event. dyadic.com/dyadic-applied-bi… #DYAI #Biotech #SyntheticBiology #PrecisionFermentation #Sidoti

Dyadic has signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic-produced recombinant proteins through IBT’s global research channels. Initial RUO products are expected to include recombinant DNase I and transferrin—marking an important step toward product-driven revenue. Read more: dyadic.com/dyadic-applied-bi… $DYAI #biotech #lifesciences

Dyadic (NASDAQ: $DYAI) & Fermbox Bio launch animal-origin-free Recombinant DNase I (RNase-free) — the first product under their expanded collaboration. Research-grade available cGMP version in development Targeting CGT & biomanufacturing markets #Dyadic #DNaseI #Biotech #CellAndGeneTherapy #AnimalFree #PrecisionFermentation dyadic.com/dyadic-and-fermbo…

Dyadic ($DYAI) & Inzymes announce planned 2026 commercialization of recombinant non-animal bovine chymosin following development milestone completion. Advancing sustainable dairy enzyme solutions via microbial fermentation. #Biotech #FoodTech #Enzymes #DYAI #Fermentation Read the full announcement here: dyadic.com/dyadic-applied-bi…

Dyadic (NASDAQ: DYAI) & Proliant announce the commercial launch of AlbuFree™ DX, a recombinant human albumin produced using Dyadic’s proprietary fungal expression platform. A key milestone converting licensed programs into recurring revenue streams. Read more:dyadic.com/dyadic-applied-bi… #Biotech #RecombinantProtein #CellCulture #AnimalFree #DYAI

Animal-free nutrition at scale Dyadic and BRIG BIO team up to commercialize recombinant bovine alpha-lactalbumin for infant, medical, and healthy aging nutrition—powered by the Dapibus™ platform. Full announcement:dyadic.com/dyadic-and-brig-b… #AltProteins #PrecisionFermentation #FoodTech #NutritionInnovation #DyadicBioSolutions

Q3 2025: Dyadic is executing. ✅New website live ✅First product orders ✅CRISPR license secured ✅Commercial shift underway Read more:dyadic.com/dyadic-announces-… #Q3Results #CRISPR #RecombinantProteins #Biotech #DyadicBioSolutions #InvestorRelations

Dyadic + CRISPR-Cas9 “This agreement gives us the ability to apply CRISPR-Cas9 to develop better strains—faster and with greater precision.” — Joe Hazelton, President & COO #CRISPR #ERSGenomics #SyntheticBiology #StrainEngineering #DyadicBioSolutions globenewswire.com/news-relea…

Dyadic expands into Japan 🇯🇵 and South Korea 🇰🇷 With Intralink, we’re bringing DNase I and Human Transferrin to Asia’s leading biologics and CGT markets. “We see meaningful opportunities…” — Joe Hazelton intralinkgroup.com/latest/ne… #Biologics #CGT #AsiaBiotech #DyadicBioSolutions #RecombinantProteins

RUO to GMP, Dyadic delivers trusted, affordable recombinant proteins [email protected] #CellCulture #RecombinantProteins #GMPReady #DNase #MRNA

Why Dyadic for Cell Culture Media? From recombinant transferrin to growth factors, Dyadic delivers animal-free, scalable, and consistent solutions to power your media formulations. Designed for flexibility. Engineered for performance. #CellCulture #RecombinantProteins #MediaOptimization #AnimalFreeBiotech #DyadicBioSolutions #Biomanufacturing #LifeScienceSolutions

Demand is rising. Costs are tight. Traditional protein production can’t keep up. Dyadic’s platform delivers high yields with industrial scalability — a better way to do recombinant production. pubs.acs.org/doi/10.1021/acs… #RecombinantSolutions #Biotech #ProteinProduction